SOURCE: Skystar Bio-Pharmaceutical Company

December 07, 2006 10:16 ET

Skystar Bio-Pharmaceutical Announces Completion of New GMP Certified Production Facilities

New Facilities Drastically Increase Production Capacity -- Company Can Now Meet a Significant Portion of the Overwhelming Demand for Its Products

XI'AN, CHINA -- (MARKET WIRE) -- December 7, 2006 -- Skystar Bio-Pharmaceutical (OTCBB: SKBI), a leading bio-pharmaceutical company in China, today announced that its new GMP certified production facilities have been completed and are fully operational. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. GMP certification is a new pharmaceutical manufacturing standard in which all pharmaceutical companies must be in compliance with to be able to sell their products in China. The increased demand for Skystar's products has been partially due to many competing firms being forced out of the industry due to these new stringent regulations.

The new facilities cover an area of over 7.74 acres and are among the most efficient and technologically advanced Bio-Pharmaceutical facilities in China. With the completion of these facilities Skystar's production capacity has drastically increased, allowing the Company to be able to meet a significant portion of the overwhelming demand for its products. The new facilities will be able to produce 6,250 metric tons of microecologics /probiotics feed additives, 50 million doses of medicines in liquid form, 200 million veterinary tablets and 3,000 metric tons of powder and other forms of veterinary medicines.

"The completion of our new facilities is a momentous milestone for us," commented Weibing Lu, Chief Executive Office of Skystar Bio-Pharmaceutical. "Understanding and predicting the impact of the new GMP regulations on pharmaceutical companies, we took the initiative and invested over $10 million in building these facilities and have been rewarded with immediate results as demand for our products has substantially increased and Skystar has become one of the leading producers of veterinary pharmaceutical products in China."

If you would like to be added to Skystar Bio-Pharmaceutical's investor email list please contact Zack Noory with Nexus Investor Relations at

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 60 state-of-the-art products with over 50 additional products in the developmental stage. One of the prominent products currently in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed strategic sales distribution networks in 27 provinces and regions throughout China. Skystar recently received China's State Ministry of Agriculture's authorization for the construction of a new Bio-Pharmaceutical facility, which will conform to Good Manufacturing Practices (GMP) standards and will significantly increase the company's production capacity. Skystar anticipates that this increase will help the company meet the overwhelming demand for its products. For additional information, please visit

Forward-looking statement: Except for the historical information, the matters discussed in this news release may contain forward-looking statements, including, but not limited to, factors relating to future sales. These forward-looking statements may involve a number of risks and uncertainties. Actual results may vary significantly based on a number of factors, including, but not limited to, uncertainties in product demand, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors detailed in the company's most recent annual report and other filings with the Securities and Exchange Commission.

Contact Information

    Scott Cramer
    Director - Investor Relations
    Email Contact

    Zack Noory
    Managing Partner
    Email Contact